• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients

Opinion
Video

Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’'s study on “"Hematologists’' Approach to Discussing Older Patients’ Values in the Context of Allogeneic Hematopoietic Cell Transplantation”" explored the methodologies hematologists use to engage older patients in treatment decisions, highlighting key findings related to patient values and the importance of incorporating these factors into transplant decision-making for improved patient-centered care.

Video content above is prompted by the following:

  • Discuss the data that was were presented at the 2024 ASH Annual Meeting titled in “Hematologists’ Approach to Discussing Older Patients’ Values in the Context of Allogeneic Hematopoietic Cell Transplantation.”
  • What was the objective of the study?
  • How was this study designed/what methodology was used?
  • What results were presented?
Related Videos
4 experts in this video
4 experts in this video
2 experts in this video
2 experts in this video
Related Content
Previous research suggests patients exposed to polypharmacy have greater risks of mortality, adverse drug reactions, and longer hospitalizations. | Image Credit: fizkes - stock.adobe.com

Number of Medications a Strong Prognostic Indicator in Lymphoma, CLL, MM

July 29th 2025
Article

Investigators found certain classes of prescriptions were also associated with outcomes, though they do not believe the association is necessarily a causal one.

Read More

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

December 17th 2024
Podcast

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Listen

Despite the benefits associated with adequate physical function in CLL, 70% of respondents said they had never received any physical activity advice from a doctor. | Image Credit: kieferpix - stock.adobe.com.jpg

Exercise Tied to Improved Symptoms, QOL in Patients With CLL

July 27th 2025
Article

While physical activity was linked with improved quality of life (QOL), the majority of patients are not given the recommendation from their doctor.

Read More

In chronic lymphocytic leukemia (CLL), TP53 has been an important subject of investigation since the early 1990s. | Image credit: MdBabul - stock.adobe.com

TP53 Mutations Remain Important Research Focus in Cancer

July 25th 2025
Article

TP53 mutations can have a significant impact on the prognosis of diseases like chronic lymphocytic leukemia, but their effect can vary based on numerous factors.

Read More

Taken together, the findings suggest that the use of venetoclax following BTKi discontinuation is a feasible strategy that may help overcome toxicity-related challenges associated with long-term BTKi use. | Image credit: jarun011 - stock.adobe.com

Venetoclax Consolidation a Feasible Strategy After BTKi in CLL

July 23rd 2025
Article

Switching to venetoclax led to sustained high rates of undetectable minimal residual disease, the investigators found.

Read More

The findings have potential implications for treatment selection in CLL/SLL, particularly in patients at elevated risk for infectious complications. | Image credit: Eleni - stock.adobe.com

Higher Infection Risk With Venetoclax-Obinutuzumab vs Zanubrutinib in CLL/SLL

July 7th 2025
Article

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) treated with venetoclax plus obinutuzumab experienced significantly higher rates of serious infections compared with those receiving zanubrutinib, according to real-world data.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.